Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical Resection

Chinese Academy of Medical Sciences & Peking Union Medical College

Status: Unknown

Conditions: Hepatocellular Carcinoma

Treatments: Drug: Sorafenib; Procedure: TACE

Study type: Interventional

Funder types: Other

Identifiers

NCT02537158

CH-GI-077

Details and patient eligibility

About

This study is a prospective non-randomized controlled study. The purpose of this study is to evaluate the validity and safety of sorafenib and transcatheter arterial chemoembolization (TACE) for microvascular invasion (MVI) in hepatocellular carcinoma (HCC) patients after radical surgery.

Full description

HCC is the sixth most common malignancy worldwide.Selected patients with HCC are candidates for potentially curative therapy, such as hepatic resection and liver transplantation. Nevertheless,tumor recurrence is 70 % at 5 years after resection and 15-30 % after liver transplantation,leading to tumor-related death.MVI is currently one of the most critical factors predictive of HCC recurrence.There are no approved effective interventional measures to improve the outcome of this patients with MVI.The purpose of this study is to explore the validity and safety of sorafenib and TACE for MVI in HCC patients after radical resection.The candidates will be assigned to sorafenib group (about 30 cases),TACE group (about 30 patients) and control group (about 30 cases)，according to the willingness of the subject.All patients will be followed up for 3 years and Recurrence-free survival and overall survival will be recorded.

Enrollment: 90 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18-75 years of age;
• The liver tumor has been radically resected;
• Postoperative pathology proved to be hepatocellular carcinoma with negative margin and microvascular invasion;
• Imaging evaluations(CT/MRI) were performed at 1 month after the resection and no area of enhancement was seen;
• Child-Pugh A;
• Eastern Cooperative Oncology Group(ECOG) body condition score (PS) 0-1;
• Then patients understand and voluntarily signed a written informed consent;

Exclusion criteria

• Recurrent HCC;
• pathology-proved multifocal HCC or HCC with satellite nodules;
• Tumor thrombus in portal vein or inferior vena cava trunk;
• Patients with extrahepatic metastasis found by radiologic or pathologic examination;
• severe dysfunction of the heart, kidney, or other organs.The patients cannot tolerate TACE or sorafenib after general assessment of the situation;
• Enrolled in other clinical study at the same time;
• Previously treated with other antitumor treatments except the resection;
• The researchers believe that the patient does not fit this study;
• Pregnant or lactating women.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

90 participants in 3 patient groups

sorafenib group

Experimental group

Description:

sorafenib group patients will accept sorafenib therapy for one year（400 mg bid,orally).

Treatment:

Drug: Sorafenib

TACE group

Experimental group

Description:

TACE group patients will accept TACE therapy once at a month after resection.

Treatment:

Procedure: TACE

control group

No Intervention group

Description:

Control group patients will not accept any intervention,except necessary supportive treatment.